Defence Therapeutics Inc.
DTCFF
$0.66
$0.047.21%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -55.92% | 75.72% | |||
| Depreciation & Amortization | -15.11% | 13.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -57.60% | 91.99% | |||
| Operating Income | 57.60% | -91.99% | |||
| Income Before Tax | 39.04% | -26.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.04% | -26.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.04% | -26.23% | |||
| EBIT | 57.60% | -91.99% | |||
| EBITDA | 58.10% | -95.73% | |||
| EPS Basic | 39.22% | -13.33% | |||
| Normalized Basic EPS | 34.83% | 9.18% | |||
| EPS Diluted | 39.22% | -13.33% | |||
| Normalized Diluted EPS | 34.83% | 9.18% | |||
| Average Basic Shares Outstanding | 0.03% | 11.16% | |||
| Average Diluted Shares Outstanding | 0.03% | 11.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||